Alport Syndrome Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Video
• Funding
• Clinical Trials

Reata Announces Initiation of Phase 2/3 Study of Bardoxolone Methyl in the Treatment of Chronic Kidney Disease Due to Alport Syndrome
IRVING, Texas, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ( “Reata” or the “Company”) today announced the initiation of patient screening in a Phase 2/3 trial to evaluate bardoxolone methyl (“bard”) in... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 23, 2017 Category: Pharmaceuticals Source Type: clinical trials

A Phase 2/3 Trial of the the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL
Condition:   Alport Syndrome Interventions:   Drug: Placebo Oral Capsule;   Drug: Bardoxolone Methyl Sponsor:   Reata Pharmaceuticals, Inc. Not yet recruiting - verified January 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2017 Category: Research Source Type: clinical trials